Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 19, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	37,845	44,744	29,316	21,731	27,358	17,834
Market Cap Growth	10.63%	52.63%	34.90%	-20.57%	53.40%	44.47%
Enterprise Value	37,896	44,786	29,263	21,965	27,663	17,475
Last Close Price	285.30	337.90	225.80	175.80	221.35	149.40
PE Ratio	141.63	167.44	-	-	-	-
PS Ratio	11.96	14.15	13.50	13.14	28.18	24.02
PB Ratio	56.31	66.57	452.40	-108.87	-184.79	34.48
P/TBV Ratio	56.31	66.57	452.40	-	-	34.48
P/FCF Ratio	95.48	112.89	-	572.67	-	-
P/OCF Ratio	84.79	100.24	-	230.62	-	-
EV/Sales Ratio	12.02	14.16	13.48	13.28	28.50	23.54
EV/EBITDA Ratio	70.69	94.37	-	-	-	-
EV/EBIT Ratio	89.01	104.84	-	-	-	-
EV/FCF Ratio	95.61	112.99	-	578.81	-	-
Debt / Equity Ratio	3.76	3.76	40.89	-12.16	-16.51	3.72
Debt / EBITDA Ratio	4.70	4.70	-	-	-	-
Debt / FCF Ratio	6.38	6.38	-	63.96	-	-
Net Debt / Equity Ratio	0.08	0.08	0.73	-1.10	-2.65	-0.42
Net Debt / EBITDA Ratio	0.11	0.11	-0.41	-1.07	-0.57	0.38
Net Debt / FCF Ratio	0.13	0.13	-1.15	5.80	-0.68	0.35
Asset Turnover	0.81	0.81	0.56	0.50	0.29	0.24
Inventory Turnover	8.46	8.46	3.86	2.85	1.57	1.74
Quick Ratio	2.51	2.51	2.61	2.86	3.17	3.79
Current Ratio	2.76	2.76	2.78	3.08	3.51	4.04
Return on Equity (ROE)	73.28%	73.28%	-	-	-526.14%	-106.31%
Return on Assets (ROA)	6.81%	6.81%	-2.74%	-4.78%	-13.65%	-12.56%
Return on Invested Capital (ROIC)	86.03%	100.88%	-255.24%	-198.35%	-261.58%	-132.10%
Return on Capital Employed (ROCE)	14.30%	14.30%	-5.80%	-9.90%	-28.30%	-24.00%
Earnings Yield	0.71%	0.60%	-0.92%	-1.83%	-3.87%	-4.21%
FCF Yield	1.05%	0.89%	-0.14%	0.18%	-2.10%	-3.54%
Buyback Yield / Dilution	-5.51%	-5.51%	-2.20%	-2.64%	-2.73%	-3.01%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.